pH-Responsive Swelling Micelles for the Treatment of Methicillin-Resistant Staphylococcus aureus Biofilms
Source abstract
Abstract
Biofilm formation exacerbates the challenge of eradicating drug-resistant bacterial infections. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major pathogens that leads to biofilm infections of the skin and soft tissue and device-associated infections. Here, we report a pH-responsive micelle that swells while releasing the loaded antibiotic, ciprofloxacin, in the low pH environment of MRSA biofilms. The antibiotic-loaded micelles were found to be more effective at eliminating MRSA biofilm bacteria and biofilm supernatant bacteria compared to treatment with free ciprofloxacin or pH-responsive micelles without encapsulated antibiotics. Blank pH-responsive micelles exhibited either comparable or greater reduction in MRSA biofilm bacteria burden compared to biofilms treated with only ciprofloxacin. Overall, our studies demonstrate the promise of using pH-swelling nanoparticles for the treatment of biofilm bacteria.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bacterial biofilms and quorum sensing · Antimicrobial Resistance in Staphylococcus · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Engineering, Center for Biomedical Engineering, Brown University, Providence, Rhode Island 02912, United States
Funding
Office of Experimental Program to Stimulate Competitive Research · Office of Naval Research
References (32)
Show source-provided references
1. 10.1128/AAC.45.4.999-1007.200110.1128/AAC.45.4.999-1007.2001 ↗
2. 10.1038/s41522-022-00306-y10.1038/s41522-022-00306-y ↗
3. 10.1126/science.284.5418.131810.1126/science.284.5418.1318 ↗
4. 10.1128/CMR.15.2.167-193.200210.1128/CMR.15.2.167-193.2002 ↗
5. 10.1038/nrmicro352110.1038/nrmicro3521 ↗
6. 10.3389/fmicb.2018.0241910.3389/fmicb.2018.02419 ↗
7. 10.1128/JCM.00501-0810.1128/JCM.00501-08 ↗
8. 10.1016/j.jinf.2013.09.01410.1016/j.jinf.2013.09.014 ↗
9. 10.1007/s11999-008-0209-410.1007/s11999-008-0209-4 ↗
10. 10.1089/mdr.2020.000110.1089/mdr.2020.0001 ↗
11. 10.1007/BF0321880310.1007/BF03218803 ↗
12. 10.3389/fmicb.2021.76158310.3389/fmicb.2021.761583 ↗
13. 10.1039/D2BM00361A10.1039/D2BM00361A ↗
14. 10.1039/C6PY01872F10.1039/C6PY01872F ↗
15. 10.1016/j.ijpharm.2018.10.00110.1016/j.ijpharm.2018.10.001 ↗
16. 10.3390/pharmaceutics1203025810.3390/pharmaceutics12030258 ↗
17. 10.1098/rsos.17165410.1098/rsos.171654 ↗
18. 10.1086/42149110.1086/421491 ↗
19. 10.15698/mic2021.05.74910.15698/mic2021.05.749 ↗
20. 10.1038/s41467-021-21718-y10.1038/s41467-021-21718-y ↗
21. 10.1128/IAI.00509-0710.1128/IAI.00509-07 ↗
22. 10.1016/j.ijbiomac.2019.04.13910.1016/j.ijbiomac.2019.04.139 ↗
23. 10.1023/A:101192160896410.1023/A:1011921608964 ↗
24. 10.1021/mz400357g10.1021/mz400357g ↗
25. 10.1038/s41579-022-00767-010.1038/s41579-022-00767-0 ↗
26. 10.1177/002203450935940310.1177/0022034509359403 ↗
27. 10.1039/C7CS00807D10.1039/C7CS00807D ↗
28. 10.1021/bm100975w10.1021/bm100975w ↗
29. 10.1021/bm501751v10.1021/bm501751v ↗
30. 10.1002/jbm.a.3664510.1002/jbm.a.36645 ↗
31. 10.1021/acsami.8b1097210.1021/acsami.8b10972 ↗
32. 10.1002/smll.20190231310.1002/smll.201902313 ↗